BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 27, 2025
See today's BioWorld Asia
Home
» Phytopharm Gets Obesity Drug Back From Pfizer, Seeks Partner
To read the full story,
subscribe
or
sign in
.
Phytopharm Gets Obesity Drug Back From Pfizer, Seeks Partner
Aug. 6, 2003
By
Nuala Moran
LONDON - Phytopharm plc fell victim to the fallout from Pfizer Inc.'s $66 billion acquisition of Pharmacia Corp., as Pfizer dropped development of P57, an obesity treatment based on a plant extract discovered by Phytopharm. (BioWorld International)
BioWorld Asia